Atazanavir + 2 NRTIs — Competitive Intelligence Brief

Atazanavir + 2 NRTIs (Atazanavir + 2 NRTIs) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor (PI) + nucleoside reverse transcriptase inhibitors (NRTIs). Area: Infectious Disease / Virology.

marketed Protease inhibitor (PI) + nucleoside reverse transcriptase inhibitors (NRTIs) HIV protease; HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Atazanavir + 2 NRTIs (Atazanavir + 2 NRTIs) — Bristol-Myers Squibb. Atazanavir inhibits HIV protease to prevent viral replication, combined with two nucleoside reverse transcriptase inhibitors (NRTIs) that block reverse transcription of viral RNA.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atazanavir + 2 NRTIs TARGET	Atazanavir + 2 NRTIs	Bristol-Myers Squibb	marketed	Protease inhibitor (PI) + nucleoside reverse transcriptase inhibitors (NRTIs)	HIV protease; HIV reverse transcriptase
Lopinavir/ritonavir + nevirapine	Lopinavir/ritonavir + nevirapine	Amsterdam UMC, location VUmc	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor)	HIV protease; HIV reverse transcriptase
Ritonavir boosted Atazanavir + Lamivudine	Ritonavir boosted Atazanavir + Lamivudine	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitor)	HIV protease; HIV reverse transcriptase
Reyataz + Epzicom	Reyataz + Epzicom	ViiV Healthcare	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
LPV/r + TDF/FTC or TDF/3TC	LPV/r + TDF/FTC or TDF/3TC	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
ATV/r + TDF/FTC or DRV/r + TDF/FTC	ATV/r + TDF/FTC or DRV/r + TDF/FTC	Juan A. Arnaiz	phase 3	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor (PI) + nucleoside reverse transcriptase inhibitors (NRTIs) class)

1. Bristol-Myers Squibb · 1 drug in this class